Boothbay Fund Management, LLC Intra Cellular Therapies, Inc. Transaction History

Boothbay Fund Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $366,909 - $431,205	5,700 New	5,700 $394,000
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $698,755 - $1.06 Million	-19,851 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $551,969 - $816,615	-19,219 Reduced 49.19%	19,851 $740,000
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $77,862 - $99,881	2,528 Added 6.92%	39,070 $1.33 Million
Q4 2020 Feb 12, 2021	SELL	$23.34 - $32.22 $221,846 - $306,251	-9,505 Reduced 20.64%	36,542 $1.16 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $810,887 - $1.47 Million	46,047 New	46,047 $1.18 Million
Q2 2020 Aug 14, 2020	SELL	$14.35 - $26.64 $888,035 - $1.65 Million	-61,884 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$12.31 - $33.12 $761,792 - $2.05 Million	61,884 New	61,884 $951,000
Q4 2018 Feb 14, 2019	SELL	$10.36 - $20.96 $176,120 - $356,320	-17,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$17.77 - $22.9 $302,090 - $389,300	17,000 New	17,000 $369,000
Q2 2018 Aug 14, 2018	SELL	$17.33 - $23.4 $195,828 - $264,420	-11,300 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$15.16 - $25.49 $171,308 - $288,037	11,300 New	11,300 $238,000

400

87.2M

309K

302K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.